HCPCS Level II code J9213 designates a 3 million unit injection of recombinant interferon alfa-2a. This code identifies the billed drug product and is used across outpatient infusion centers, oncology and infectious disease clinics, and physician offices where injectable biologic therapies are administered. Nationally, accurate use of J9213 matters for claims processing, clinical documentation, and tracking utilization of interferon-based therapies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for interferon alfa-2a injections, typical sites of service, and the role of the code in billing workflows. The publication also summarizes benchmarking and payer coverage themes, common modifier usage, and where to expect policy updates affecting billing and reimbursement.

This resource is intended to help billing managers, practice administrators, and health policy analysts understand the clinical identity of J9213, the payer landscape, and the types of operational and policy information relevant to managing claims for this injectable therapy.